Cari M Kitahara1, Dóra K Rmendiné Farkas2, Jens Otto L Jørgensen3, Deirdre Cronin-Fenton2, Henrik Toft Sørensen2. 1. Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 2. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus C, Denmark. 3. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus C, Denmark.
Abstract
Context: Thyroid nodules, adenomas, and goiter have consistently been associated with thyroid cancer risk. Few studies have assessed whether thyroid dysfunction and thyroid autoimmunity influence this risk. Objective: To examine thyroid cancer risk after diagnoses of a wide range of benign thyroid conditions. Design: Hospital and cancer registry linkage cohort study for the years 1978 to 2013. Setting: Nationwide (Denmark). Participants: Patients diagnosed with hyperthyroidism (n = 85,169), hypothyroidism (n = 63,143), thyroiditis (n = 12,532), nontoxic nodular goiter (n = 65,782), simple goiter (n = 11,582), other/unspecified goiter (n = 21,953), or adenoma (n = 6,481) among 8,258,807 residents of Denmark during the study period. Main Outcome Measures: We computed standardized incidence ratios (SIRs) for differentiated thyroid cancer, excluding the first 12 months of follow-up after benign thyroid disease diagnosis. Results: SIRs were significantly elevated for all benign thyroid diseases apart from hypothyroidism. SIRs were higher for men than women and in the earlier follow-up periods. Elevated SIRs were observed for localized and regional/distant thyroid cancer. After excluding the first 10 years of follow-up, hyperthyroidism [n = 27 thyroid cancer cases; SIR = 2.00; 95% confidence interval (CI): 1.32 to 2.92], nontoxic nodular goiter (n = 83; SIR = 4.91; 95% CI: 3.91 to 6.09), simple goiter (n = 8; SIR = 4.33; 95% CI: 1.87 to 8.53), other/unspecified goiter (n = 20; SIR = 3.94; 95% CI: 2.40 to 6.08), and adenoma (n = 9; SIR = 6.02; 95% CI: 2.76 to 11.5) remained positively associated with thyroid cancer risk. Conclusions: We found an unexpected increased risk of differentiated thyroid cancer, including regional/distant disease, following diagnosis of hyperthyroidism and thyroiditis that could not be solely attributed to increased medical surveillance. Hypothyroidism was less clearly associated with thyroid cancer risk.
Context: Thyroid nodules, adenomas, and goiter have consistently been associated with thyroid cancer risk. Few studies have assessed whether thyroid dysfunction and thyroid autoimmunity influence this risk. Objective: To examine thyroid cancer risk after diagnoses of a wide range of benign thyroid conditions. Design: Hospital and cancer registry linkage cohort study for the years 1978 to 2013. Setting: Nationwide (Denmark). Participants: Patients diagnosed with hyperthyroidism (n = 85,169), hypothyroidism (n = 63,143), thyroiditis (n = 12,532), nontoxic nodular goiter (n = 65,782), simple goiter (n = 11,582), other/unspecifiedgoiter (n = 21,953), or adenoma (n = 6,481) among 8,258,807 residents of Denmark during the study period. Main Outcome Measures: We computed standardized incidence ratios (SIRs) for differentiated thyroid cancer, excluding the first 12 months of follow-up after benign thyroid disease diagnosis. Results: SIRs were significantly elevated for all benign thyroid diseases apart from hypothyroidism. SIRs were higher for men than women and in the earlier follow-up periods. Elevated SIRs were observed for localized and regional/distant thyroid cancer. After excluding the first 10 years of follow-up, hyperthyroidism [n = 27 thyroid cancer cases; SIR = 2.00; 95% confidence interval (CI): 1.32 to 2.92], nontoxic nodular goiter (n = 83; SIR = 4.91; 95% CI: 3.91 to 6.09), simple goiter (n = 8; SIR = 4.33; 95% CI: 1.87 to 8.53), other/unspecifiedgoiter (n = 20; SIR = 3.94; 95% CI: 2.40 to 6.08), and adenoma (n = 9; SIR = 6.02; 95% CI: 2.76 to 11.5) remained positively associated with thyroid cancer risk. Conclusions: We found an unexpected increased risk of differentiated thyroid cancer, including regional/distant disease, following diagnosis of hyperthyroidism and thyroiditis that could not be solely attributed to increased medical surveillance. Hypothyroidism was less clearly associated with thyroid cancer risk.
Authors: Donald S A McLeod; Karen F Watters; Anthony D Carpenter; Paul W Ladenson; David S Cooper; Eric L Ding Journal: J Clin Endocrinol Metab Date: 2012-05-23 Impact factor: 5.958
Authors: S Franceschi; S Preston-Martin; L Dal Maso; E Negri; C La Vecchia; W J Mack; A McTiernan; L Kolonel; S D Mark; K Mabuchi; F Jin; G Wingren; R Galanti; A Hallquist; E Glattre; E Lund; F Levi; D Linos; E Ron Journal: Cancer Causes Control Date: 1999-12 Impact factor: 2.506
Authors: Cari L Meinhold; Elaine Ron; Sara J Schonfeld; Bruce H Alexander; D Michal Freedman; Martha S Linet; Amy Berrington de González Journal: Am J Epidemiol Date: 2009-11-30 Impact factor: 4.897
Authors: Briseis A Kilfoy; Tongzhang Zheng; Theodore R Holford; Xuesong Han; Mary H Ward; Andreas Sjodin; Yaqun Zhang; Yana Bai; Cairong Zhu; Grace L Guo; Nathaniel Rothman; Yawei Zhang Journal: Cancer Causes Control Date: 2008-11-19 Impact factor: 2.506
Authors: Morten Schmidt; Sigrun Alba Johannesdottir Schmidt; Jakob Lynge Sandegaard; Vera Ehrenstein; Lars Pedersen; Henrik Toft Sørensen Journal: Clin Epidemiol Date: 2015-11-17 Impact factor: 4.790
Authors: G Cortês Nascimento; A G P de Araujo Cortês Nascimento; C de Maria Ribeiro Veiga Parente; V P Rodrigues; R S de Sousa Azulay; V C de Carvalho Rocha; S da Silva Pereira Damianse; M Magalhães; M Dos Santos Faria; M B Gomes Journal: J Endocrinol Invest Date: 2020-07-17 Impact factor: 4.256
Authors: So Young Kim; Dae Myoung Yoo; Mi Jung Kwon; Ji Hee Kim; Joo-Hee Kim; Woo Jin Bang; Sung Kyun Kim; Hyo Geun Choi Journal: J Pers Med Date: 2022-05-27
Authors: Sara J Schonfeld; Lindsay M Morton; Amy Berrington de González; Rochelle E Curtis; Cari M Kitahara Journal: Cancer Epidemiol Date: 2019-12-26 Impact factor: 2.984
Authors: Cari M Kitahara; Dagrun Slettebø Daltveit; Anders Ekbom; Anders Engeland; Mika Gissler; Ingrid Glimelius; Tom Grotmol; Ylva Trolle Lagerros; Laura Madanat-Harjuoja; Tuija Männistö; Henrik Toft Sørensen; Rebecca Troisi; Tone Bjørge Journal: Lancet Diabetes Endocrinol Date: 2020-12-18 Impact factor: 32.069
Authors: Jonathan Mark Fussey; Robin N Beaumont; Andrew R Wood; Bijay Vaidya; Joel Smith; Jessica Tyrrell Journal: J Clin Endocrinol Metab Date: 2020-07-01 Impact factor: 5.958